These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34902571)

  • 21. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
    Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
    Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
    Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
    Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
    Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
    Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
    Santillan C; Fowler K; Kono Y; Chernyak V
    Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim SS; Chang DR; Kim H; Kim MJ
    Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria.
    Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
    AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538
    [No Abstract]   [Full Text] [Related]  

  • 28. The diagnostic value of contrast-enhanced ultrasound LI-RADS for hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis B.
    Yang D; Hu H; Li R; Tang CL; Ma KS; Guo DY
    Abdom Radiol (NY); 2022 Feb; 47(2):630-639. PubMed ID: 34910237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification.
    Smereka P; Doshi AM; Lavelle LP; Shanbhogue K
    AJR Am J Roentgenol; 2020 Aug; 215(2):382-389. PubMed ID: 32432909
    [No Abstract]   [Full Text] [Related]  

  • 30. Percentages of Hepatocellular Carcinoma in LI-RADS Categories with CT and MRI: A Systematic Review and Meta-Analysis.
    Lee S; Kim YY; Shin J; Son WJ; Roh YH; Choi JY; Sirlin CB; Chernyak V
    Radiology; 2023 Apr; 307(1):e220646. PubMed ID: 36625748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
    Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?
    Tan Z; Teoh WC; Wong KM; Wansaicheong GK; Sandrasegaran K
    Clin Imaging; 2020 Jun; 62():63-68. PubMed ID: 32070868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
    Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations.
    Sevco TJ; Masch WR; Maturen KE; Mendiratta-Lala M; Wasnik AP; Millet JD
    AJR Am J Roentgenol; 2021 Sep; 217(3):644-650. PubMed ID: 34259543
    [No Abstract]   [Full Text] [Related]  

  • 38. Outcomes of LI-RADS US-2 Subthreshold Observations Detected on Surveillance Ultrasound.
    Tse JR; Shen L; Bird KN; Yoon L; Kamaya A
    AJR Am J Roentgenol; 2022 Nov; 219(5):774-783. PubMed ID: 35703411
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term evolution of LR-2, LR-3 and LR-4 observations in HBV-related cirrhosis based on LI-RADS v2018 using gadoxetic acid-enhanced MRI.
    Xing F; Zhang T; Miao X; Lu J; Du S; Jiang J; Xing W
    Abdom Radiol (NY); 2023 Dec; 48(12):3703-3713. PubMed ID: 37740759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP.
    Li CQ; Huang H; Ruan SM; Hu HT; Xian MF; Xie XY; Lu MD; Kuang M; Wang Y; Chen LD
    Abdom Radiol (NY); 2022 Apr; 47(4):1311-1320. PubMed ID: 35122491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.